Regardless of political affiliation, one thing unites Americans in 2025: frustration with our healthcare system. As costs skyrocket, coverage becomes more complex, and regulatory uncertainty mounts, employers are left to navigate a dizzying array of policy shifts, rising drug prices, and compliance burdens all while trying to deliver benefits employees actually value.
Healthcare reform has long been a third rail in American politics, but recent data shows dissatisfaction is hitting historic highs. Between 2008 and 2022, the cost of private health insurance per enrollee surged over 60%. At the same time, the rate of coverage denials across ACA marketplace plans averages nearly 1 in 5 claims. That’s a painful mismatch of price and performance.
And it matters to your workforce. In a recent Forbes survey, two-thirds of American employees ranked employer-sponsored healthcare as the #1 most important benefit when deciding whether to accept a job. Yet for employers, offering robust coverage is becoming harder than ever.
Here are three key policy and cost issues employers should watch in 2025, and how they might affect your plan strategy.
- Preventive Care Coverage Under Threat
A Supreme Court case this year could determine whether the Affordable Care Act’s no-cost preventive care mandate remains intact. The challenge argues that the U.S. Preventive Services Task Force (USPSTF), which recommends which services must be covered was unconstitutionally appointed and oversteps its authority.
If the Court sides with the challengers, employers may no longer be required to provide certain preventive services without cost-sharing. That could offer short-term savings but beware the long-term risks. Cost barriers reduce utilization, and that can drive more expensive care down the line. Skipping a $0 cancer screening today could mean paying for chemotherapy tomorrow.
Action for Employers: Maintain no-cost preventive services unless legally excused and weigh cost-sharing changes carefully against downstream costs.
- Climbing Prescription Drug Costs
Pharmacy spending for outpatient prescription drugs is projected to outpace inflation rates, with drug costs expected to grow 11.4% in 2025. The forces fueling this surge include:
- GLP-1s (like Ozempic and Wegovy) for diabetes and weight loss cost $900 to $1,300/month and are rapidly expanding in use and indications.
- Specialty drugs now represent half of total drug spend, including gene therapies with million-dollar price tags.
- Biosimilars, once expected to drive down costs, have been slow to gain traction due to formulary barriers and lack of awareness.
- Tariffs on imported drugs could send prices even higher for plan sponsors.
Action for Employers:
- Reevaluate GLP-1 coverage policies—consider restricting weight-loss-only use or using step therapy.
- Engage PBMs on biosimilar adoption strategies.
- Explore copay accumulator programs to reduce specialty drug costs.
- Prepare for possible price shocks tied to pharmaceutical tariffs.
- Mental Health Parity Compliance is Evolving
Mental health parity rules have expanded again. The 2024 Final Rules under the Mental Health Parity and Addiction Equity Act (MHPAEA) introduce stricter compliance and reporting standards, especially for non-quantitative treatment limitations like provider access and prior authorization requirements.
Legal challenges against the new rules are already underway, with ERIC, a key employer trade group, filing suit against the government in January of this year. Meanwhile, enforcement remains patchy amid federal staffing cuts and administrative transitions.
Action for Employers:
- Stay current on MHPAEA litigation outcomes and federal enforcement updates.
- Work with carriers to review comparative analyses and ensure parity compliance.
- Budget for potential reporting and operational costs if the new rules are upheld.
RazorMetrics Is an Easier Way to Manage Prescription Costs
In a year where plan sponsors face mounting legal complexity, rising pharmacy inflation, and volatile policy changes, one area remains squarely within your control: the way you manage prescription drug spending.
At RazorMetrics, we help employers lower drug costs without disrupting prescriber workflows or overwhelming members. Our AI-driven solution identifies lower-cost therapeutic equivalents and routes requests through physicians first—ensuring clinical integrity and member trust.
Members only hear from us after their doctor approves the switch. The result? Lower out-of-pocket costs for employees and real savings for your plan — without friction.
Ready to see how it works?
Schedule a demo or contact us to learn how RazorMetrics can bring clarity and savings to your 2025 benefits strategy.
This blog is based on insights from a legal analysis authored by Jennifer L. Malik and Anna R. Hosack, attorneys with Babst Calland. Malik focuses on healthcare benefits administration, insurance coverage, and appellate law, while Hosack concentrates on municipal law and healthcare benefits law. We thank them for their thoughtful and comprehensive review of the current healthcare landscape.
